Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing packed with pharmacology terms is hard enough—doing it for Matinas Biopharma (MTNB), where every footnote could hint at the future of oral amphotericin B, is tougher. Clinical burn rates, orphan-drug milestones, and lipid-crystal nanoparticle data sprawl across hundreds of pages, making it challenging to pinpoint what truly moves the stock.
Our platform solves that problem. Stock Titan’s AI delivers real-time Matinas Biopharma Form 4 insider transactions, decodes complex 10-K risk factors, and flags fresh 8-K trial updates the moment they hit EDGAR. Need the Matinas Biopharma quarterly earnings report 10-Q filing summarized? Our AI highlights cash runway changes, R&D spend, and pending FDA interactions in plain English. You’ll also find:
- Matinas Biopharma insider trading Form 4 transactions with context on executive confidence
- Matinas Biopharma annual report 10-K simplified for easy review of pipeline progress
- Side-by-side earnings report filing analysis across quarters
- Matinas Biopharma proxy statement executive compensation details without the legalese
- Matinas Biopharma 8-K material events explained so you catch every trial read-out
Whether you’re understanding Matinas Biopharma SEC documents with AI before committing capital or tracking Matinas Biopharma executive stock transactions Form 4 for sentiment cues, our expert summaries replace hours of manual digging. Stay ahead of pivotal disclosures, monitor clinical milestones, and make decisions with confidence—no PhD in pharmacology required.
Matinas BioPharma Holdings, Inc. (MTNB) has filed a Form S-8 with the SEC on 23 June 2025 to register securities issuable under its new 2025 Equity Incentive Plan. The filing designates the company as a non-accelerated filer and smaller reporting company. Plan information required by Section 10(a) is omitted from this registration statement and will be provided directly to eligible service providers in accordance with Rule 428.
The company incorporates by reference its recent SEC filings, including: (a) the Form 10-K for the year ended 31 December 2024 (filed 15 April 2025); (b) the Form 10-Q for the quarter ended 31 March 2025 (filed 15 May 2025); (c) eleven Form 8-K filings between 10 January and 23 June 2025; and (d) the description of its common stock contained in its Form 8-A (as updated).
Standard undertakings are provided to file post-effective amendments for material changes, and the company reiterates Delaware General Corporation Law (DGCL) indemnification provisions for directors and officers. Exhibits will be listed in the Exhibit Index (not included in the excerpt). Jerome D. Jabbour, Chief Executive Officer, is named as the agent for service, with Lowenstein Sandler LLP serving as counsel.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
What is the core focus of Matinas Biopharm?
What technology does Matinas Biopharm use in its drug development?
What are the main candidates in Matinas Biopharm's pipeline?
How does Matinas Biopharm differentiate its products from traditional formulations?
Which infections are targeted by Matinas Biopharm's lead candidates?
In what clinical phases are the lead candidates currently?
How does Matinas Biopharm's technology impact the current anti-infective treatment landscape?
